Biodegradable and Biocompatible Bioactive-based Polymers for Dental Applications

Invention Summary: The Uhrich group at Rutgers University has developed various biodegradable polymers that chemically incorporate bioactive molecules, such as nonsteroidal anti-inflammatory drugs (e.g., salicylic acid), and antibiotics (e.g., amoxicillin). Bioactive molecules are incorporated into polymer backbones through labile linkages, enabling high bioactive loading and sustained and controlled release upon degradation (e.g., hydrolysis). The release profile is well controlled based on the polymer chemical compositions and can be adjusted to desired release time frame (from hours, days, to months). The polymers have great potential for localized release and their patented synthetic approaches are highly flexible to accommodate other bioactives of interest with different functionalities such as phenols and carboxylates.  Compared with bioactives themselves, the polymers can be easily formulated into various geometries for applications requiring microspheres, hydrogels, films, and/or disks.  Further, polymeric versions of bioactives are more stable on storage than the bioactives alone. Our newly developed aromatic polyanhydrides have improved degradation, processing and solubility properties, as well as therapeutic utilities. They are particularly useful in enhancing regeneration and healing of tissue as validated in vivo with mouse model. Market Applications: Novel materials that are anti-inflammatory, antimicrobial, and promote healing through enhanced tissue regeneration (e.g., hard tissue or soft tissue) Can be used alone or as medical device/device coatings for dental implants, bone grafts and other orthopedic and surgical applications Advantages: Applicable to a variety of natural bioactives Tunable and controlled bioactive release profile High bioactive content in polymer Ease of formulation into different geometries and formulations Possible to incorporate other bioactive agents for synergistic effect Intellectual Property & Development Status: IP portfolio including US6685928 B2 and US7396527 B2 in U.S.; claims broadly cover both compositions and synthetic methods. Available for licensing and/or research collaboration.